Reserpine for the Treatment of Cocaine Dependence - 1

Phase 2, Double-Blind, Placebo-Controlled Trial of Reserpine for the Treatment of Cocaine Dependence

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00033033

Enrollment

140

Registered

2002-04-08

Start date

2001-07-31

Completion date

2003-05-31

Last updated

2017-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cocaine-Related Disorders, Substance-Related Disorders

Keywords

cocaine dependence

Brief summary

The purpose of this study is to assess the efficacy and safety of reserpine for the treatment of cocaine dependence.

Detailed description

To assess the efficacy and safety of reserpine in reducing cocaine use in subjects with cocaine dependence. This is a double-blind, placebo-controlled, parallel-group design with a 2 week baseline period.

Interventions

DRUGReserpine

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 99 Years

Healthy volunteers

Inclusion criteria

Be at least 18 yrs of age; DSM-4 diagnosis of cocaine dependence; treatment seeking individuals; have the ability to understand and provide written informed consent; females of child bearing potential using appropriate birth control method

Exclusion criteria

Additional criteria available during screening at the site.

Design outcomes

Primary

Measure	Time frame
Cocaine use	—
Addiction severity	—
Cocaine withdrawal	—
Adverse events	—
Clinical improvement	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 8, 2026